Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Honeywell

QuidelOrtho Corp

Sony

Billionaire investor Mario Gabelli (Trades, Portfolio), leader of New York-based GAMCO Investors, disclosed his third-quarter portfolio earlier this week.

Mario Gabelli's Top 5 Trades of the 3rd Quarter

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn't mean that they don't have occasional colossal losses; they do (like Peltz's recent General Electric losses). However, it is still a good idea to keep an eye on hedge fund activity. With this in mind, as the current round of 13F filings has just ended, let's examine the smart money sentiment towards Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Hedge Funds Made A Bundle From Momenta Pharmaceuticals, Inc. (MNTA)

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of its sale to Johnson & Johnson for $52.50 per share, totaling approximately $6.5 billion.

Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson

AstraZeneca

Biogen

Neoleukin Therapeutics Inc

Perrigo

Relmada Therapeutics Inc

Sanofi

Supernus Pharmaceuticals

Takeda Pharmaceutical

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Pharmaceutical Stocks for Q4 2020

CAMBRIDGE, Mass., Sept.  15, 2020  (GLOBE NEWSWIRE) --  Momenta Pharmaceuticals, Inc.  (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with the all-cash tender offer by Vigor Sub, Inc. (“Vigor”), a wholly owned subsidiary of Johnson & Johnson (“Johnson & Johnson” or “J&J”), for all the outstanding shares of Momenta common stock for $52.50 per share (the “Offer Price”).  The tender offer, which commenced on September 2, 2020, is being made pursuant to the previously announced merger agreement among Johnson & Johnson, Vigor and Momenta, dated August 19, 2020 (the “Merger Agreement”).

Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?

Why Is Momenta (MNTA) Up 86.9% Since Last Earnings Report?

New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/62869_411c215894893897_001full.jpgTo: All Perso

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation into the Fairness of the Sale of Momenta Pharmaceuticals, Inc. to Johnson & Johnson

Momenta Pharmaceuticals stock was thrust into the financial headlines and might look tempting, but don't forget that price is king.
The post Buyout Excitement Is Already Priced Into Momenta Pharmaceuticals appeared first on InvestorPlace.

Buyout Excitement Is Already Priced Into Momenta Pharmaceuticals

Johnson & Johnson

Johnson & Johnson has increased its dividend for 58 years in a row (a dividend king) and presently has a yield of 2.7%, which is above average.

Johnson & Johnson: Accelerating Their Virus Vaccine Development And The Buy Of Momenta With Debt Is A Good Move

Johnson & Johnson to enroll 60,000 participants in the late-stage trial for its COVID-19 vaccine.

Johnson & Johnson to acquire Momenta Pharmaceuticals for $6.5 billion

Johnson & Johnson (NYSE: JNJ) is borrowing $7.5 billion in bonds to help fund its purchase of Momenta Pharmaceuticals, Inc (NASDAQ: MNTA) as a series of companies tap the debt market to finance merger and acquisitions, Bloomberg reported Thursday.

Johnson & Johnson Borrows $7.5B To Fund Its Purchase Of Momenta

New York, New York--(Newsfile Corp. - August 20, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Momenta Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Momenta Pharmaceuticals, Inc. to Johnson & Johnson

J&J (JNJ) offers to buy Momenta, which focuses on the development of novel drugs to treat rare, immune-mediated disorders.

J&J to Buy Momenta for $6.5B to Boost Autoimmune Presence

The stock price of Momenta Pharmaceuticals, a pharmaceutical company best known for its immunology therapies, has rallied around 26% over recent weeks (vs. about a 50% gain in the S&P 500) to $31 as of August 18, after falling to a low of $24 in late March, when a rapid increase in the number.

Is Momenta A Good Fit For JNJ?

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Momenta Pharmaceuticals, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc.

BioMarin Pharmaceutical

The Fed spoiled the party for the stock market.

Nasdaq Falls Off Record Levels; Momenta, BioMarin Head in Opposite Directions

Momenta Pharmaceuticals (MNTA) news for Wednesday includes a deal with Johnson & Johnson (JNJ) sending MNTA stock rocketing higher.

Momenta Pharmaceuticals News: MNTA Stock Rockets 69% on JNJ Deal

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Momenta Pharmaceuticals, Inc.

INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Momenta Pharmaceuticals, Inc. - MNTA

A healthcare titan is acquiring the biotech in a $6.5 billion deal.

Why Momenta Pharmaceuticals Stock Rocketed 69% Higher Today

The company is paying a big premium to expand its autoimmune disease treatment footprint.

Johnson & Johnson to Acquire Momenta Pharmaceuticals for $6.5 Billion in Cash

Johnson & Johnson will buy Momenta Pharmaceuticals for $6.5 billion to broaden its reach in treating autoimmune and rare diseases.
The post Johnson & Johnson To Acquire Momenta Pharmaceuticals For $6.5 Billion appeared first on Investor's Business Daily.

Johnson & Johnson  To Acquire Momenta Pharmaceuticals For $6.5 Billion

SAN DIEGO, Aug. 19, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Momenta Pharmaceuticals, Inc.

(MNTA) Alert: Johnson Fistel Investigates Proposed Sale of Momenta Pharmaceuticals; Are Shareholders Getting a Fair Price?

Shares of Momenta Pharmaceuticals Inc. MNTA, +5.04% rocketed 69% into record territory in premarket trading Wednesday, after the biotechnology company announced an agreement to be acquired by Johnson & Johnson JNJ, +0.73% in a deal valued at $6.5 billion.

Momenta Pharmaceuticals' stock rockets after $6.5 billion buyout deal with Johnson & Johnson

Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals Inc for about $6.5 billion in cash to expand into the area of autoimmune disease treatments.

Johnson & Johnson to buy Momenta for about $6.5 billion

CAMBRIDGE, Mass., Aug.  19, 2020  (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases announced today that it has entered into a definitive agreement for Johnson & Johnson (“Johnson & Johnson” or “J&J”) to acquire Momenta for $52.50 per share in an all-cash transaction, implying a fully-diluted equity value of $6.5 billion. The agreement was unanimously approved by the Boards of Directors of both Momenta and Johnson & Johnson.

News for Momenta Pharmaceuticals Stock (MNTA)